Skip to main content

Table 1 Baseline patient demographics and clinical characteristics

From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Characteristic Erlotinib GC P value
Median age at diagnosis (years) 60.17 ± 13.31 58.75 ± 12.12 0.71
Gender, n (%)    0.68
Male 6 (6/12, 50.00 %) 8 (8/12, 66.67 %)  
Female 6 (6/12, 50.00 %) 4 (4/12, 33.33 %)  
Smoking duration 6.25 ± 11.89 20.83 ± 21.09 0.10
Daily cigarette consumption, n 7.92 ± 14.99 17.92 ± 18.27 0.18
Pathology, n (%)    1.00
Adeno 11 (11/12, 91.67 %) 11 (11/12, 91.67 %)  
LCNEC 0 (0.00 %) 1 (1/12, 8.33 %)  
Adenoid cystic carcinoma 1 (1/12, 8.33 %) 0 (0.00 %)  
Mutation status, n (%)    <0.001
EGFR/KRAS wild type 0 11  
KRAS 0 1  
Exon 19 deletion 6 0  
L858R 4 0  
EGFR mutation with KRAS codon 1 0  
12/13*    
EGFR mutation with EML4-ALK* 1 0  
Deletion in BIM 2/8 0/9  
Postoperative radiotherapy, n 3/6 2/7 0.59
Median follow-up (months) 19.3 (5.8–64.0) 35.6 (1.7–68.7) 0.41
  1. EGFR epidermal growth factor receptor, LCNEC large-cell neuroendocrine carcinoma, GC gemcitabine/carboplatin, BIM Bcl-2-interacting mediator of cell death
  2. *Two patients in the erlotinib arm with the EGFR L855R mutation also had the KRAS mutation or EML4-ALK translocation